Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01472016
Title Study of ABT-700 in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie (prior sponsor, Abbott)
Indications

Advanced Solid Tumor

Therapies

Docetaxel

ABT-700

Cetuximab

Erlotinib

Fluorouracil + Irinotecan + Leucovorin

Age Groups: senior | adult
Covered Countries


No variant requirements are available.